COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients
COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients
复制标题
DOI：
10.21873/anticanres.12375
复制
发表时间：
2018-03-01
影响因子：
2
通讯作者：
Bieche, Ivan
中科院分区：
文献类型：
--
作者：
De Cremoux, Patricia;Hamy, Anne-Sophie;Bieche, Ivan
背景资料：环氧化酶-2（COX 2）在乳腺癌中的预后和预测作用仍有争议，特别是其作为COX 2抑制剂（塞来昔布）在新辅助治疗中的靶点。材料与方法：我们分析了REMAGUS-02随机II期试验中COX 2治疗组患者的156例乳腺癌样本。COX 2基因表达通过逆转录和定量聚合酶链反应使用冷冻活检组织中的核糖核酸进行评估。病理完全缓解（pCR）是替代终点。结果如下：在COX 2表达最高的肿瘤中，观察到3级和雌激素和孕激素受体阴性的比率显著较高。在接受塞来昔布治疗的患者中，COX 2过表达肿瘤的pCR率显著较高。COX 2基因表达和塞来昔布效应之间的相互作用检验具有统计学显著性（p
Background: The prognostic and predictive role of cyclo-oxygenase-2 (COX2) in breast cancer is still debated, and in particular, its role as a target of COX2 inhibitor (celecoxib) in neoadjuvant setting. Materials and Methods: We analyzed a series of 156 breast cancer samples from patients of the COX2 inhibitor-treated arm included in the REMAGUS-02 randomized phase II trial. COX2 gene expression was assessed by reverse transcription and quantitative polymerase chain reaction using ribonucleic acid from frozen biopsies. Pathological complete response (pCR) was the surrogate endpoint. Results: Significantly higher rates of grade 3, and estrogen and progesterone receptor negativity were observed in tumors with the highest expression of COX2. pCR rates were significantly higher in COX2-overexpressing tumors in patients receiving celecoxib. The test for interaction between COX2 gene expression and the celecoxib effect was statistically significant (p